Federica Sotgia

Dr. Federica Sotgia


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Cell Cycle
Verified
Journal Article
Open access
PDF file
SPStephanos Pavlides
Stephanos Pavlides
DWDiana Whitaker-Menezes
Diana Whitaker-Menezes
RCRemedios Castello-Cros
Remedios Castello-Cros
NFNeal Flomenberg
Neal Flomenberg
AWAgnieszka K. Witkiewicz
Agnieszka K. Witkiewicz
MLMichael P. Lisanti
Michael P. Lisanti
Here, we propose a new model for understanding the Warburg effect in tumor metabolism. Our hypothesis is that epithelial cancer cells induce the Warburg effect (aerobic glycolysis) in neighboring stromal fibroblasts. These cancer-associated fibroblasts, then undergo myo-fibroblastic differentiation, and secrete lactate and pyruvate (energy metabolites resulting from aerobic glycolysis). Epithelial cancer cells could then take up these energy-rich metabolites and use them in the mitochondrial TCA cycle, thereby promoting efficient energy production (ATP generation via oxidative phosphorylation), resulting in a higher proliferative capacity. In this alternative model of tumorigenesis, the epithelial cancer cells instruct the normal stroma to transform into a wound-healing stroma, providing the necessary energy-rich micro-environment for facilitating tumor growth and angiogenesis. In essence, the fibroblastic tumor stroma would directly feed the epithelial cancer cells, in a type of host-parasite relationship. We have termed this new idea the "Reverse Warburg Effect." In this scenario, the epithelial tumor cells "corrupt" the normal stroma, turning it into a factory for the production of energy-rich metabolites. This alternative model is still consistent with Warburg's original observation that tumors show a metabolic shift towards aerobic glycolysis. In support of this idea, unbiased proteomic analysis and transcriptional profiling of a new model of cancer-associated fibroblasts (caveolin-1 (Cav-1) deficient stromal cells), shows the up-regulation of both i) myo-fibroblast markers and ii) glycolytic enzymes, under normoxic conditions. We validated the expression of these proteins in the fibroblastic stroma of human breast cancer tissues that lack stromal Cav-1. Importantly, a loss of stromal Cav-1 in human breast cancers is associated with tumor recurrence, metastasis, and poor clinical outcome. Thus, an absence of stromal Cav-1 may be a biomarker for the "Reverse Warburg Effect", explaining its powerful predictive value.

4 May 2016 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
UMUbaldo E. Martinez-Outschoorn
Ubaldo E. Martinez-Outschoorn
MPMaria Peiris-Pagés
Maria Peiris-Pagés
RPRichard G. Pestell
Richard G. Pestell
FSFederica Sotgia
Federica Sotgia
Michael P. LisantiMichael P. Lisanti
Michael P. Lisanti

1 April 1998 in Nature Genetics
Verified
Journal Article
Closed access
CMCarlo Minetti
Carlo Minetti
FSFederica Sotgia
Federica Sotgia
CBClaudio Bruno
Claudio Bruno
PSPaolo Scartezzini
Paolo Scartezzini
PBPaolo Broda
Paolo Broda
FZFederico Zara
Federico Zara

1 September 2010 in Cell Cycle
Verified
Journal Article
Open access
GBGloria Bonuccelli
Gloria Bonuccelli
ATAristotelis Tsirigos
Aristotelis Tsirigos
DWDiana Whitaker-Menezes
Diana Whitaker-Menezes
SPStephanos Pavlides
Stephanos Pavlides
RPRichard G. Pestell
Richard G. Pestell
Michael P. LisantiMichael P. Lisanti
Michael P. Lisanti
Previously, we proposed a new model for understanding the "Warburg effect" in tumor metabolism. In this scheme, cancer-associated fibroblasts undergo aerobic glycolysis and the resulting energy-ric...

22 January 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
RLRebecca Lamb
Rebecca Lamb
BOBela Ozsvari
Bela Ozsvari
CLCamilla L. Lisanti
Camilla L. Lisanti
HTHerbert B. Tanowitz
Herbert B. Tanowitz
AHAnthony Howell
Anthony Howell
Michael P. LisantiMichael P. Lisanti
Michael P. Lisanti
Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease

24 May 2016 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MPMaria Peiris-Pagès
Maria Peiris-Pagès
UMUbaldo E. Martinez-Outschoorn
Ubaldo E. Martinez-Outschoorn
RPRichard G. Pestell
Richard G. Pestell
FSFederica Sotgia
Federica Sotgia
Michael P. LisantiMichael P. Lisanti
Michael P. Lisanti
Cancer is now viewed as a stem cell disease. There is still no consensus on the metabolic characteristics of cancer stem cells, with several studies indicating that they are mainly glycolytic and others pointing instead to mitochondrial metabolism as their principal source of energy. Cancer stem cells also seem to adapt their metabolism to microenvironmental changes by conveniently shifting energy production from one pathway to another, or by acquiring intermediate metabolic phenotypes. Determining the role of cancer stem cell metabolism in carcinogenesis has become a major focus in cancer research, and substantial efforts are conducted towards discovering clinical targets.